Pfizer has said Lipitor (R) (atorvastatin calcium) 80 mg significantly reduced risk of major cardiovascular ailments in patients with heart disease, type 2 diabetes and chronic kidney disease, including heart attack and stroke, by 35 per cent compared with Lipitor 10 mg.
The results of these findings were published in the August issue of Mayo Clinic proceedings.
"As the rate of diabetes in the US has gone up, we have noticed a dramatic rise in cases of chronic kidney disease," said James Shepherd, clinical academic consultant, department of pathological biochemistry, University of Glasgow Medical School and a member of the TNT steering committee. "This trend is alarming, since patients with diabetes and chronic kidney disease are much more likely to suffer a heart attack or stroke than patients with diabetes alone, increasing the urgency to treat. The study's findings support existing norms that call for aggressively lowering LDL cholesterol by statin therapy, such as Lipitor 80 mg, to reduce the chances of a heart attack or stroke in these high-risk patients."
In patients with heart disease and type 2 diabetes but without chronic kidney disease, Lipitor 80 mg reduced the risk of major cardiovascular events by 10 per cent compared to Lipitor 10 mg, which did not reach significant standards. |
